US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Accustem Sciences Inc.

0.2796

+0.01877.17%

Volume:20.57K

Turnover:6.01K

Market Cap:4.49M

PE:-2.40

High:0.3200

Open:0.2609

Low:0.2609

Close:0.2609

52wk High:2.33

52wk Low:0.2609

Shares:16.07M

Float Shares:9.92M

Volume Ratio:163.49

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1163

ROE:-1794.16%

ROA:-72.64%

PB:-1.16

PE(LYR):- -

Loading ...

Overview Company News Filings

AccuStem net loss widens 10% to $485,883 in Q1 FY26

Accustem FY25 net loss widens 16.68% to $1,756,096

Accustem Sciences delays filing annual report, expects 10-K within 15 days

AccuStem Sciences Partners with NSABP for StemPrintER Pilot Study

Accustem Sciences MSC Lung Cancer Test Enters Medicare Coverage Review Queue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ACUT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACUT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUT\",,,,,undefined,":{"symbol":"ACUT","market":"US","secType":"STK","nameCN":"Accustem Sciences Inc.","latestPrice":0.279594,"timestamp":1779120420000,"preClose":0.2609,"halted":0,"volume":20573,"delay":15,"changeRate":0.07165197393637404,"floatShares":9922079,"shares":16072267,"eps":-0.1163,"marketStatus":"Trading","change":0.018694,"latestTime":"05-18 12:07:00 EDT Delay","open":0.2609,"high":0.32,"low":0.2609,"amount":6005.24964788,"amplitude":0.226524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.1163,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1779134400000},"marketStatusCode":2,"adr":0,"exchange":"OTCQB","adjPreClose":0.2609,"volumeRatio":163.494759},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUT\",,,,,undefined,":{"symbol":"ACUT","floatShares":9922079,"roa":"-72.64%","roe":"-1794.16%","lyrEps":0,"volumeRatio":163.494759,"shares":16072267,"dividePrice":0,"high":0.32,"amplitude":0.226524,"preClose":0.2609,"low":0.2609,"week52Low":0.2609,"pbRate":"-1.16","week52High":2.33,"institutionHeld":0,"latestPrice":0.279594,"eps":-0.1163,"divideRate":0,"volume":20573,"delay":15,"ttmEps":-0.1163,"open":0.2609,"prevYearClose":0.81351,"prevWeekClose":0.2609,"prevMonthClose":0.28,"prevQuarterClose":0.38,"fiveDayClose":0.2609,"twentyDayClose":0.32,"sixtyDayClose":0.4703},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACUT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-16","symbol":"ACUT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1726459200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-20","symbol":"ACUT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1716177600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACUT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACUT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACUT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635371120","title":"AccuStem net loss widens 10% to $485,883 in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635371120","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635371120?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:10","pubTimestamp":1778875824,"startTime":"0","endTime":"0","summary":"Accustem Sciences posted a net loss of $485,883 for three months ended March 31, 2026, widening 10% from a year earlier; operating loss also widened 10% to $485,883.Research and development expenses more than quadrupled to $119,525, up 322%, while general and administrative costs fell 11% to $366,358.Cash and cash equivalents ended period at $12,207, down from $13,929 at start of quarter; cash used in operating activities rose to $374,176 from $290,182.Company reiterated plan to launch MSC lung test for clinical use in early 2027, with transfer of MSC to partner lab EmeritusDx under way ahead of CLIA certification and reimbursement efforts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7XzfQX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627642436","title":"Accustem FY25 net loss widens 16.68% to $1,756,096","url":"https://stock-news.laohu8.com/highlight/detail?id=2627642436","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627642436?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:33","pubTimestamp":1776198821,"startTime":"0","endTime":"0","summary":"Accustem Sciences posted a net loss of $1,756,096, widening 16.68%.Operating loss widened to $1,756,096 as research and development expense more than doubled to $281,014.General and administrative costs rose 8% to $1,475,082 on higher public relations, travel and professional fees.Accustem completed a commercial lab agreement with EmeritusDx and expects existing cash of $13,929 to fall short of funding needs beyond January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL7d4TM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514557","title":"Accustem Sciences delays filing annual report, expects 10-K within 15 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514557","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514557?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:57","pubTimestamp":1775005023,"startTime":"0","endTime":"0","summary":"Accustem Sciences disclosed a delay in filing its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Management expects to file within 15 calendar days following original due date.Filing was delayed due to time constraints tied to compiling, disseminating, and reviewing required information.Notice indicated no anticipated significant change in results of operations versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1krTJh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACUT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601366464","title":"AccuStem Sciences Partners with NSABP for StemPrintER Pilot Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601366464","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601366464?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873628,"startTime":"0","endTime":"0","summary":"AccuStem Sciences Ltd. has announced a partnership with the National Surgical Adjuvant Breast and Bowel Project  to conduct a pilot study evaluating the StemPrintER test in a subset of patients from the B-32 cohort. This collaboration aims to validate the predictive capabilities of StemPrintER, a diagnostic test that stratifies early stage breast cancer patients by recurrence risk based on tumor \"stemness.\" Positive results from this study could have significant implications for surgical planning and patient outcomes in breast cancer care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2KXgK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014005.SGD","IE00BKPKM429.USD","NDAQ","ACUT","BK4139","SG9999014013.SGD","LU2210150020.SGD","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586256260","title":"Accustem Sciences MSC Lung Cancer Test Enters Medicare Coverage Review Queue","url":"https://stock-news.laohu8.com/highlight/detail?id=2586256260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586256260?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:16","pubTimestamp":1764191800,"startTime":"0","endTime":"0","summary":"Accustem Sciences Ltd. has announced that its application for a local coverage determination for its MSC test has been accepted as complete and valid by Novitas Solutions, a Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services  in the JL region. The application will now enter the regulatory review queue. The MSC test is a non-invasive blood-based assay designed to assess lung cancer risk in patients who qualify for screening or have indeterminate pulmonary nodules. No other organizations are mentioned as recipients of this review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLpCPWp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACUT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}